Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders

Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and... Background: The polymorphic enzyme CYP2C19 is of importance for the metabolism and effects of omeprazole during short‐term treatment. Aim: To investigate the relationship between CYP2C19 genotype and the effects of long‐term omeprazole treatment. Material and methods: A total of 180 patients with acid related disorders were genotyped for wild type and mutated CYP2C19 alleles by allele‐specific PCR amplification. Gastrin and chromogranin A were assessed by radioimmunoassays, and pepsinogen I and H. pylori serology were assessed by ELISA methods. Results: In 108 of the patients, who received a single dose of 20 mg omeprazole, there was no difference in gastrin and chromogranin A concentrations between the three CYP2C19 genotypes. In 72 patients on long‐term treatment (> 1 year) with 20 mg omeprazole daily, serum gastrin as well as plasma chromogranin A concentrations (mean ± s.e.) were both about threefold higher in the wild type/mutated (52.1 ± 7.6 p M and 7.3 ± 1.3 n M (n=19), respectively) compared to wild type/wild type (14.7 ± 0.9 p M and 2.5 ± 0.1 n M (n=52), respectively; both comparisons P=0.0001). In a single mutated/mutated patient on long‐term treatment, both gastrin and chromogranin A were high (88 p M and 13.7 n M, respectively). Serum pepsinogen I concentration was significantly lower in wild type/mutated (n=19) patients on long‐term treatment, compared with the corresponding wild type/wild type (n=49) group (147 ± 19 μg/L vs. 193 ± 12 μg/L, P=0.04). Conclusion: Patients with one (and probably also with two) mutated CYP2C19 allele(s) on long‐term treatment with omeprazole had significantly affected serum gastrin and pepsinogen I and plasma chromogranin A concentrations compared with patients with two normal alleles. This indicates that changes in gastric mucosal morphology during omeprazole treatment might be dependent upon the degree of the individual’s capacity to metabolize omeprazole. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alimentary Pharmacology & Therapeutics Wiley

Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders

Download PDF
8 pages

Loading next page...
 
/lp/wiley/omeprazole-and-cyp2c19-polymorphism-effects-of-long-term-treatment-on-MLDmS0WR7g

References (55)

Publisher
Wiley
Copyright
Copyright © 2000 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0269-2813
eISSN
1365-2036
DOI
10.1046/j.1365-2036.2000.00835.x
Publisher site
See Article on Publisher Site

Abstract

Background: The polymorphic enzyme CYP2C19 is of importance for the metabolism and effects of omeprazole during short‐term treatment. Aim: To investigate the relationship between CYP2C19 genotype and the effects of long‐term omeprazole treatment. Material and methods: A total of 180 patients with acid related disorders were genotyped for wild type and mutated CYP2C19 alleles by allele‐specific PCR amplification. Gastrin and chromogranin A were assessed by radioimmunoassays, and pepsinogen I and H. pylori serology were assessed by ELISA methods. Results: In 108 of the patients, who received a single dose of 20 mg omeprazole, there was no difference in gastrin and chromogranin A concentrations between the three CYP2C19 genotypes. In 72 patients on long‐term treatment (> 1 year) with 20 mg omeprazole daily, serum gastrin as well as plasma chromogranin A concentrations (mean ± s.e.) were both about threefold higher in the wild type/mutated (52.1 ± 7.6 p M and 7.3 ± 1.3 n M (n=19), respectively) compared to wild type/wild type (14.7 ± 0.9 p M and 2.5 ± 0.1 n M (n=52), respectively; both comparisons P=0.0001). In a single mutated/mutated patient on long‐term treatment, both gastrin and chromogranin A were high (88 p M and 13.7 n M, respectively). Serum pepsinogen I concentration was significantly lower in wild type/mutated (n=19) patients on long‐term treatment, compared with the corresponding wild type/wild type (n=49) group (147 ± 19 μg/L vs. 193 ± 12 μg/L, P=0.04). Conclusion: Patients with one (and probably also with two) mutated CYP2C19 allele(s) on long‐term treatment with omeprazole had significantly affected serum gastrin and pepsinogen I and plasma chromogranin A concentrations compared with patients with two normal alleles. This indicates that changes in gastric mucosal morphology during omeprazole treatment might be dependent upon the degree of the individual’s capacity to metabolize omeprazole.

Journal

Alimentary Pharmacology & Therapeutics – Wiley

Published: Nov 27, 2000

There are no references for this article.